ZURICH (Reuters) - Actelion, Europe's largest biotech company, confirmed its full-year outlook on Thursday ahead of a widely anticipated approval of its big drug hope Opsumit by U.S. health regulators later this week. Nine month sales of its main product Tracleer, a treatment for pulmonary arterial hypertension (PAH), rose 3 percent to 1.138 billion Swiss francs, while net profit was 304 million francs. Actelion confirmed its forecast for core earnings to cross into the double-digit percentage range for 2013. (Reporting by Alice Baghdjian and Caroline Copley)
via Health News Headlines - Yahoo! News http://news.yahoo.com/actelion-confirms-outlook-sales-rise-053836011--finance.html
No comments:
Post a Comment